Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in HCC Refractory to Checkpoint Inhibitors
NCT04588051Phase 2Active, not recruiting
- Start
- Nov 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in hepatocellular carcinoma (HCC). Primary endpoint: Progression-Free Survival at 1 year. Started Nov 2020; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04588051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588051.